Your browser is no longer supported. Please, upgrade your browser.
Settings
EXEL Exelixis, Inc. daily Stock Chart
EXEL [NASD]
Exelixis, Inc.
Index- P/E143.76 EPS (ttm)0.19 Insider Own1.00% Shs Outstand293.55M Perf Week9.73%
Market Cap7.98B Forward P/E42.45 EPS next Y0.64 Insider Trans-33.76% Shs Float276.46M Perf Month-3.00%
Income58.20M PEG3.13 EPS next Q0.08 Inst Own81.00% Short Float7.23% Perf Quarter-3.34%
Sales319.70M P/S24.95 EPS this Y63.70% Inst Trans0.10% Short Ratio5.18 Perf Half Y27.56%
Book/sh0.51 P/B53.27 EPS next Y137.04% ROA10.40% Target Price29.71 Perf Year131.43%
Cash/sh1.19 P/C22.84 EPS next 5Y46.00% ROE59.70% 52W Range10.04 - 32.50 Perf YTD82.23%
Dividend- P/FCF54.37 EPS past 5Y-19.90% ROI-15.10% 52W High-16.40% Beta1.90
Dividend %- Quick Ratio4.10 Sales past 5Y-7.90% Gross Margin96.70% 52W Low170.62% ATR1.32
Employees287 Current Ratio4.10 Sales Q/Q172.70% Oper. Margin22.90% RSI (14)55.23 Volatility6.53% 4.50%
OptionableYes Debt/Eq0.00 EPS Q/Q137.30% Profit Margin18.20% Rel Volume0.71 Prev Close27.46
ShortableYes LT Debt/Eq0.00 EarningsNov 02 AMC Payout0.00% Avg Volume3.86M Price27.17
Recom2.30 SMA206.96% SMA502.48% SMA20018.00% Volume2,740,852 Change-1.06%
Oct-17-17Reiterated RBC Capital Mkts Outperform $33 → $39
Oct-17-17Reiterated Needham Buy $30 → $33
Oct-16-17Reiterated SunTrust Buy $32 → $35
Sep-22-17Downgrade Leerink Partners Outperform → Mkt Perform
Sep-15-17Initiated RBC Capital Mkts Outperform $32
Sep-12-17Reiterated Needham Buy $28 → $30
Jul-14-17Initiated SunTrust Buy $33
Mar-31-17Initiated Needham Buy $28
Mar-16-17Initiated Oppenheimer Perform
Feb-28-17Downgrade Stifel Buy → Hold $21 → $22
Nov-03-16Initiated Deutsche Bank Buy $17
Oct-10-16Upgrade Piper Jaffray Neutral → Overweight
Sep-15-16Reiterated Stifel Buy $12 → $15
Aug-04-16Reiterated Stifel Buy $10 → $12
Jun-21-16Reiterated Leerink Partners Outperform $8 → $10
Apr-26-16Reiterated Stifel Buy $7 → $8
Apr-04-16Upgrade Stifel Hold → Buy $7
Jan-19-16Upgrade Leerink Partners Mkt Perform → Outperform
Sep-02-14Downgrade Stifel Buy → Hold
Feb-07-14Reiterated Stifel Buy $9 → $11
Oct-20-17 05:28PM  Cancer Treatment Update: Second Gene Therapy Receives Approval Zacks
10:12AM  ETFs with exposure to Exelixis, Inc. : October 20, 2017 Capital Cube
Oct-19-17 08:00AM  Exelixis, Positive News from Celestial Study, Cabometyx Label Review Due February 15, 2018 ACCESSWIRE
Oct-18-17 04:05PM  Exelixis to Release Third Quarter 2017 Financial Results on Wednesday, November 1, 2017 Business Wire
07:50AM  Featured Company News - Exelixis' Cabozantinib Met Primary Endpoint in Phase-3 CELESTIAL Trial for Advanced Hepatocellular Carcinoma ACCESSWIRE
07:32AM  Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug Zacks
Oct-17-17 10:03AM  Company News For Oct 17, 2017 Zacks
09:15AM  FDA Grants Priority Review for Exelixis' RCC Drug Cabomteyx Zacks
08:33AM  Exelixis (EXEL) Looks Good: Stock Adds 17.2% in Session Zacks
08:18AM  Why Exelixis' Rebound Is Just Getting Started Motley Fool
08:10AM  Today's Research Reports on Stocks to Watch: Dynavax and Exelixis ACCESSWIRE
08:05AM  Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : October 17, 2017 Capital Cube
Oct-16-17 05:04PM  What Happened in the Stock Market Today Motley Fool +17.21%
04:40PM  Exelixis Rockets To 17-Year High On Kidney, Liver Cancer News Investor's Business Daily
04:32PM  Exelixis and Ruby Tuesday rise while Nordstrom and Tesla dip Associated Press
03:49PM  Wall Street High on Monday GuruFocus.com
12:57PM  Why Exelixis, Inc. Rose Higher Today Motley Fool
09:22AM  Exelixis Pops on Phase 3 Data for Liver Cancer Drug -- Biotech Movers TheStreet.com
09:22AM  Exelixis Pops as FDA Gives Kidney Cancer Drug Priority Review -- Biotech Movers TheStreet.com
09:10AM  Exelixis Cancer Treatment Hits Key Milestone 24/7 Wall St.
07:26AM  Exelixis shares surge 19% premarket after FDA grants priority review to kidney cancer drug MarketWatch
07:15AM  Exelixis cancer drug meets key goal in late-stage trial Reuters
07:02AM  Ipsen Announces That Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma Business Wire
06:59AM  Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX® (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell Carcinoma Business Wire
06:58AM  Exelixis Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma Business Wire
Oct-12-17 02:35PM  Top 5 Biotech Stocks for 2017 Investopedia
Oct-09-17 11:30AM  ETFs with exposure to Exelixis, Inc. : October 9, 2017 Capital Cube
08:04AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Oct-06-17 09:11AM  Exelixis, Inc. :EXEL-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017 Capital Cube
08:15AM  New Research: Key Drivers of Growth for Bed Bath and Beyond, The Finish Line, Exelixis, Garmin, Juno Therapeutics, and Mattel - A Look Behind the Scenes at Consolidated Results, Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Oct-05-17 10:37AM  The 2 Surprising Reasons Exelixis, Inc. Lost 17% in September Motley Fool
07:42AM  Could Cabometyx Be Exelixiss Long-Term Growth Driver? Market Realist
Oct-04-17 05:35PM  How Is Cabometyx and Cometriq Positioned after 1H17? Market Realist
04:43PM  Why These Biotechs Are Leading The Group Near A 21-Month High Investor's Business Daily
04:06PM  How Did Exelixis Perform in 1H17? Market Realist
02:11PM  Analyst Recommendations for Exelixis in October 2017 Market Realist
08:00AM  Exelixis to Receive Milestone Payment from Bristol-Myers Squibb for Submission of Clinical Trial Authorization for RORt Inverse Agonist Program Business Wire
Oct-02-17 02:00PM  3 Beaten-Down Biotech Stocks to Buy Right Now Motley Fool
08:02AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Sep-30-17 10:47AM  Better Buy: Exelixis, Inc. vs. Immunogen, Inc. Motley Fool
Sep-26-17 08:18AM  3 Reasons to Buy the Dip With Exelixis Motley Fool
Sep-25-17 08:20AM  Today's Research Reports on Stocks to Watch: Exelixis and Versartis ACCESSWIRE
08:19AM  Exelixis, Inc. breached its 50 day moving average in a Bearish Manner : EXEL-US : September 25, 2017 Capital Cube
Sep-24-17 09:00PM  Exelixis Provides Update on Collaborator Daiichi Sankyos Phase 3 Clinical Progress with Esaxerenone (CS-3150), Including Positive Top-Line Results and Additional Pivotal Study Business Wire
09:09AM  3 Monster Biotech Stocks in the Making Motley Fool
Sep-22-17 03:01PM  Why Exelixis, Inc. Slumped Today Motley Fool -12.64%
06:08AM  These 3 Stocks Are Priced for Perfection. Can They Deliver? Motley Fool
Sep-20-17 06:32AM  Why Exelixis Wouldn't Be a Warren Buffett Stock Motley Fool
05:37AM  [$$] Exelixis CEO, CFO Sell $11 Million in Stock Barrons.com
Sep-19-17 04:05PM  Exelixis to Present at the Cantor Fitzgerald Healthcare Conference on September 25 Business Wire
Sep-15-17 01:18PM  Why Amgen, Lilly, J&J Are Interested In These Small Biotechs Investor's Business Daily
06:04AM  Who Will Win the Kidney Cancer Battle Between Bristol-Myers Squibb and Exelixis? Motley Fool
Sep-14-17 08:21PM  Exelixis, Inc. Value Analysis (NASDAQ:EXEL) : September 15, 2017 Capital Cube
03:19PM  Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale Motley Fool
Sep-13-17 09:44AM  Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : September 13, 2017 Capital Cube
Sep-11-17 10:10AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Sep-10-17 07:17AM  Why Exelixis, Inc. Could Be a Gold Mine for Growth Investors Motley Fool
Sep-09-17 06:09PM  Exelixis and Ipsen Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017 Business Wire
Sep-08-17 03:22PM  Exelixis Recovers From Bristol-Inspired Pitfall In Kidney Cancer Investor's Business Daily
10:34AM  2 Big Reasons Exelixis, Inc. Added $626 Million to Its Market Cap in August Motley Fool
10:23AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
06:08AM  Good News for Opdivo Shows Why You Shouldn't Give Up on Bristol-Myers Squibb Stock Motley Fool
Sep-07-17 08:16AM  Exelixis Debuts New Mission-Driven Corporate Branding That Supports Upcoming Milestones and Growth Strategy Business Wire -8.91%
Sep-06-17 05:23PM  Exelixis to Co-Host Investor/Media Briefing to Discuss Data Presented at the ESMO 2017 Congress Business Wire
Sep-02-17 08:09AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Sep-01-17 08:47AM  Can Exelixis (EXEL) Run Higher on Strong Earnings Estimate Revisions? Zacks
08:03AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Aug-31-17 08:00AM  Today's Research Reports on Trending Tickers: Exelixis, Inc. and Incyte Corporation ACCESSWIRE
Aug-29-17 04:05PM  Exelixis to Present at the Morgan Stanley Global Healthcare Conference on September 13 Business Wire
01:59PM  Analyst Recommendations for Regeneron Pharmaceuticals in August Market Realist
Aug-27-17 03:04PM  Can Buying Exelixis Stock Still Make You Rich? Motley Fool
Aug-24-17 10:35AM  4 of the Highest-Growth Stocks in Biotech Today Motley Fool
08:02AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Aug-18-17 07:40AM  Corporate News Blog - Exelixis Submits US Supplemental New Drug Application for CABOMETYX(R) for the Treatment of Previously Untreated Advanced Kidney Cancer ACCESSWIRE
Aug-17-17 05:59PM  Exelixis Submits sNDA for Kidney Cancer Drug Cabometyx Zacks
12:31PM  Edited Transcript of EXEL earnings conference call or presentation 2-Aug-17 9:00pm GMT Thomson Reuters StreetEvents
08:03AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Aug-16-17 09:45AM  Biotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis TheStreet.com
08:00AM  Today's Research Reports on Trending Tickers: Exelixis Inc. and Sarepta Therapeutics Inc. ACCESSWIRE
07:00AM  Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX® (cabozantinib) for the Treatment of Previously Untreated Advanced Kidney Cancer Business Wire
Aug-15-17 04:22PM  Why Gilead Sciences Might Not Make an Oncology Acquisition Motley Fool
Aug-14-17 01:06PM  What Amgens Analysts Recommend in August 2017 Market Realist
08:03AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Aug-11-17 08:02AM  IHS Markit Score upgrades Exelixis Inc to 72 out of 100, despite ranking positively in only one IHS Markit category. Markit
Aug-09-17 11:18AM  Exelixis, Inc. Continued Its Winning Ways and Rose 10% in July Thanks to These 3 Catalysts Motley Fool
Aug-04-17 04:35PM  Juno Therapeutics (JUNO) Q2 Loss Widens, Revenues Surpass Zacks
02:50PM  Exelixis, Inc. Grows Revenue, Eyes Treating More Patients Motley Fool
10:12AM  Agenus (AGEN) Q2 Loss Narrower Than Expected, Revenues Lag Zacks
Aug-03-17 04:41PM  Conatus (CNAT) Q2 Loss Narrows Y/Y, Revenues Beat Estimates Zacks
04:21PM  Exelixis (EXEL) Q2 Earnings, Sales Beat on Cabometyx Sales Zacks
03:41PM  3 Reasons to Still Buy Exelixis Stock After Its Strong Q2 Performance Motley Fool
02:41PM  The Risk/Reward Potential For Exelixis Has Balanced As Catalysts Loom Benzinga
11:33AM  Dynavax Technologies Corporation (DVAX) Has the Market Buzzing with Heplisav Approval at the Finish Line, Exelixis, Inc. (EXEL) Refractory RCC Drug Going Strong in its Launch SmarterAnalyst
01:07AM  Exelixis tops Street 2Q forecasts Associated Press
Aug-02-17 04:05PM  Exelixis Announces Second Quarter 2017 Financial Results and Provides Corporate Update Business Wire
12:20PM  Investor Network: Exelixis, Inc. to Host Earnings Call ACCESSWIRE
10:24AM  Corcept (CORT) Q2 Earnings Beat Estimates, Guidance Raised Zacks
Aug-01-17 10:46AM  Intercept (ICPT) Posts Narrower-than-Expected Loss in Q2 Zacks
08:00AM  Exelixis-Discovered Compounds to Be Featured in 10 Presentations at ESMO 2017 Congress Business Wire
Jul-31-17 01:56PM  ImmunoGen (IMGN) Q2 Loss Narrows, Sales & Cash Outlook Up Zacks
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company's products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 28Option Exercise9.9133,334330,340216,339Sep 28 07:45 PM
Hessekiel JeffreyEVP and General CounselSep 28Option Exercise1.9025,00047,500292,946Sep 28 07:47 PM
Hessekiel JeffreyEVP and General CounselSep 28Sale24.3225,000608,000267,946Sep 28 07:47 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 28Sale23.7433,334791,349183,005Sep 28 07:45 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 27Option Exercise9.9133,333330,330216,338Sep 28 07:45 PM
Hessekiel JeffreyEVP and General CounselSep 27Option Exercise1.902,3024,374270,248Sep 28 07:47 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 27Sale23.9433,333797,992183,005Sep 28 07:45 PM
Hessekiel JeffreyEVP and General CounselSep 27Sale23.902,30255,018267,946Sep 28 07:47 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 26Option Exercise9.9133,333330,330216,338Sep 28 07:45 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 26Sale23.6833,333789,325183,005Sep 28 07:45 PM
PAPADOPOULOS STELIOSDirectorSep 22Sale25.4010,000254,0000Sep 22 07:07 PM
PAPADOPOULOS STELIOSDirectorSep 19Sale27.63127,7903,530,8381,034,314Sep 20 06:48 PM
PAPADOPOULOS STELIOSDirectorSep 18Sale27.7672,2102,004,5501,162,104Sep 20 06:48 PM
MORRISSEY MICHAELPresident and CEOSep 14Option Exercise1.70100,000170,000160,000Sep 14 07:14 PM
Haley Patrick J.Sr. Vice President, CommercialSep 14Sale27.2160,6401,650,01441,553Sep 15 06:43 PM
MORRISSEY MICHAELPresident and CEOSep 14Sale27.08100,0002,708,00060,000Sep 14 07:14 PM
MORRISSEY MICHAELPresident and CEOSep 13Option Exercise1.70100,000170,000160,000Sep 14 07:14 PM
MORRISSEY MICHAELPresident and CEOSep 13Sale27.04100,0002,704,00060,000Sep 14 07:14 PM
WILLSEY LANCEDirectorSep 13Sale26.9750,0001,348,500468,273Sep 14 07:18 PM
MORRISSEY MICHAELPresident and CEOSep 12Option Exercise1.70100,000170,000160,000Sep 14 07:14 PM
Senner Christopher J.EVP and CFOSep 12Option Exercise3.66100,000366,000202,759Sep 14 07:17 PM
WILLSEY LANCEDirectorSep 12Sale26.7950,0001,339,500518,273Sep 14 07:18 PM
Senner Christopher J.EVP and CFOSep 12Sale26.79100,0002,679,000102,759Sep 14 07:17 PM
MORRISSEY MICHAELPresident and CEOSep 12Sale26.59100,0002,659,00060,000Sep 14 07:14 PM
Haley Patrick J.Sr. Vice President, CommercialMay 30Sale18.465,00092,300102,193Jun 01 07:09 PM
FELDBAUM CARL BDirectorMay 15Option Exercise8.7519,000166,19067,721May 16 09:13 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMay 15Option Exercise5.0412,50163,005183,005May 16 09:12 PM
FELDBAUM CARL BDirectorMay 15Sale21.5832,988711,83134,733May 16 09:13 PM
MORRISSEY MICHAELPresident and CEOMay 10Option Exercise1.86100,000185,910160,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 10Sale22.07100,0002,207,00060,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 09Option Exercise1.90100,000190,000111,214May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 09Sale21.69100,0002,168,70660,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 08Option Exercise1.9011,30021,47071,300May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 08Sale21.8111,300246,45360,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 05Option Exercise1.90100,000190,000149,555May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 05Sale21.85100,0002,184,70260,000May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 04Option Exercise1.9059,149112,383119,149May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 04Sale22.1759,1491,311,33360,000May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 03Option Exercise1.90100,000190,000129,427May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 03Sale22.67100,0002,266,80360,000May 05 06:53 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMay 01Option Exercise9.9189,910891,008260,414May 03 08:02 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMay 01Sale23.0189,9102,068,519170,504May 03 08:02 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOApr 17Option Exercise9.9110,09099,992168,143Apr 18 07:57 PM
MARCHESI VINCENT TDirectorApr 03Option Exercise10.5310,000105,300130,070Apr 04 08:00 PM
MARCHESI VINCENT TDirectorApr 03Sale21.3010,000213,000120,070Apr 04 08:00 PM
WYSZOMIERSKI JACK LDirectorMar 31Option Exercise10.5310,000105,30078,110Mar 31 06:35 PM
WYSZOMIERSKI JACK LDirectorMar 31Sale21.575,150111,08672,960Mar 31 06:35 PM
COHEN CHARLESDirectorMar 27Option Exercise10.5310,000105,300248,180Mar 28 08:15 PM
Hessekiel JeffreyEVP and General CounselMar 27Sale21.026,884144,702267,946Mar 28 08:15 PM
Hessekiel JeffreyEVP and General CounselMar 22Option Exercise1.7055,00093,500301,617Mar 24 07:41 PM
Hessekiel JeffreyEVP and General CounselMar 22Sale20.5423,787488,585277,830Mar 24 07:41 PM
PAPADOPOULOS STELIOSDirectorMar 20Option Exercise10.5310,000105,3001,238,471Mar 21 07:28 PM
FELDBAUM CARL BDirectorMar 20Option Exercise10.5310,000105,30058,721Mar 21 07:29 PM
FELDBAUM CARL BDirectorMar 20Sale21.7710,000217,70048,721Mar 21 07:29 PM
PAPADOPOULOS STELIOSDirectorMar 20Sale21.6610,000216,6001,228,471Mar 21 07:28 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMar 15Option Exercise6.2050,007310,179208,060Mar 17 07:51 PM
WILLSEY LANCEDirectorMar 15Option Exercise10.5310,000105,300578,273Mar 17 07:52 PM
WILLSEY LANCEDirectorMar 15Sale22.8610,000228,600568,273Mar 17 07:52 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMar 15Sale22.5350,0071,126,658158,053Mar 17 07:51 PM
COHEN CHARLESDirectorMar 13Sale21.8210,000218,200238,180Mar 14 08:12 PM
MARCHESI VINCENT TDirectorMar 10Option Exercise3.1340,000125,200160,070Mar 10 07:37 PM
MARCHESI VINCENT TDirectorMar 10Sale21.9840,000879,200120,070Mar 10 07:37 PM
MORRISSEY MICHAELPresident and CEOMar 06Option Exercise9.91100,000991,000160,000Mar 07 07:56 PM
MORRISSEY MICHAELPresident and CEOMar 06Sale22.61100,0002,261,00060,000Mar 07 07:56 PM
Hessekiel JeffreyEVP and General CounselMar 03Option Exercise7.27100,000727,000346,617Mar 07 08:00 PM
MORRISSEY MICHAELPresident and CEOMar 03Option Exercise9.91100,000991,000160,000Mar 07 07:56 PM
Senner Christopher J.EVP and CFOMar 03Sale22.8011,000250,800100,398Mar 03 08:20 PM
Haley Patrick J.Sr. Vice President, CommercialMar 03Sale23.042,50057,600107,193Mar 07 07:45 PM
MORRISSEY MICHAELPresident and CEOMar 03Sale22.83100,0002,283,00060,000Mar 07 07:56 PM
Hessekiel JeffreyEVP and General CounselMar 03Sale23.04100,0002,303,678246,617Mar 07 08:00 PM
POSTE GEORGEDirectorMar 02Option Exercise4.5167,400303,660144,955Mar 03 08:17 PM
POSTE GEORGEDirectorMar 02Sale22.5867,4001,521,89277,555Mar 03 08:17 PM
POSTE GEORGEDirectorMar 01Option Exercise10.538,85093,19186,405Mar 03 08:17 PM
Lamb PeterEVP, Scientific Strategy & CSOMar 01Option Exercise7.3645,000331,350118,600Mar 03 08:18 PM
Lamb PeterEVP, Scientific Strategy & CSOMar 01Sale22.1945,000998,55073,600Mar 03 08:18 PM
POSTE GEORGEDirectorMar 01Sale22.188,850196,29377,555Mar 03 08:17 PM
Lamb PeterEVP, Scientific Strategy & CSOFeb 01Option Exercise6.9270,000484,300143,600Feb 03 07:55 PM
Lamb PeterEVP, Scientific Strategy & CSOFeb 01Sale18.6570,0001,305,50073,600Feb 03 07:55 PM
Lamb PeterEVP, Scientific Strategy & CSOJan 03Option Exercise5.7470,000401,800143,600Jan 05 08:25 PM
Lamb PeterEVP, Scientific Strategy & CSOJan 03Sale14.6570,0001,025,63673,600Jan 05 08:25 PM
FELDBAUM CARL BDirectorDec 16Option Exercise10.4125,000260,25073,721Dec 16 07:29 PM
FELDBAUM CARL BDirectorDec 16Sale17.0325,000425,75048,721Dec 16 07:29 PM
Garber Alan MDirectorDec 09Option Exercise10.5310,000105,30069,161Dec 09 08:02 PM
Garber Alan MDirectorDec 09Sale16.907,832132,36161,329Dec 09 08:02 PM
SCANGOS GEORGE ADirectorDec 07Option Exercise8.993563,2001,463,824Dec 07 07:03 PM
SCANGOS GEORGE ADirectorDec 07Sale17.901763,1501,463,648Dec 07 07:03 PM
SCANGOS GEORGE ADirectorDec 05Option Exercise8.99357,9763,218,2041,668,186Dec 07 07:03 PM
SCANGOS GEORGE ADirectorDec 05Sale17.81204,7183,646,0281,463,468Dec 07 07:03 PM
Schwab GiselaPres Prod Dev & Med Aff & CMODec 01Option Exercise8.9922,000197,780180,053Dec 02 07:13 PM
Lamb PeterEVP, Scientific Strategy & CSODec 01Option Exercise5.2770,000368,800143,600Dec 02 07:14 PM
Lamb PeterEVP, Scientific Strategy & CSODec 01Sale16.6670,0001,166,20073,600Dec 02 07:14 PM
Schwab GiselaPres Prod Dev & Med Aff & CMODec 01Sale16.7322,000368,060158,053Dec 02 07:13 PM
Lamb PeterEVP, Scientific Strategy & CSONov 09Option Exercise5.1770,000362,000143,600Nov 14 07:34 PM
Schwab GiselaPres Prod Dev & Med Aff & CMONov 09Option Exercise8.9922,000197,780180,053Nov 14 07:36 PM
MORRISSEY MICHAELPresident and CEONov 09Option Exercise8.99200,0001,798,000260,000Nov 14 07:37 PM
MORRISSEY MICHAELPresident and CEONov 09Sale15.00200,0003,000,00060,000Nov 14 07:37 PM
Schwab GiselaPres Prod Dev & Med Aff & CMONov 09Sale15.0022,000330,000158,053Nov 14 07:36 PM
Lamb PeterEVP, Scientific Strategy & CSONov 09Sale13.1570,000920,50073,600Nov 14 07:34 PM
SPSC SPS Commerce, Inc. daily Stock Chart
SPSC [NASD]
SPS Commerce, Inc.
Index- P/E116.13 EPS (ttm)0.52 Insider Own0.10% Shs Outstand17.20M Perf Week3.07%
Market Cap1.05B Forward P/E57.79 EPS next Y1.05 Insider Trans-5.43% Shs Float17.14M Perf Month8.66%
Income9.10M PEG5.16 EPS next Q0.20 Inst Own- Short Float2.90% Perf Quarter3.61%
Sales206.60M P/S5.07 EPS this Y21.60% Inst Trans-0.24% Short Ratio4.95 Perf Half Y6.46%
Book/sh16.22 P/B3.75 EPS next Y20.21% ROA2.90% Target Price69.11 Perf Year-11.28%
Cash/sh9.22 P/C6.60 EPS next 5Y22.50% ROE3.50% 52W Range48.11 - 73.16 Perf YTD-12.93%
Dividend- P/FCF53.39 EPS past 5Y-21.00% ROI1.80% 52W High-16.83% Beta1.11
Dividend %- Quick Ratio5.50 Sales past 5Y27.20% Gross Margin66.60% 52W Low26.48% ATR1.25
Employees1217 Current Ratio5.50 Sales Q/Q14.60% Oper. Margin5.60% RSI (14)64.42 Volatility2.19% 2.22%
OptionableYes Debt/Eq0.00 EPS Q/Q410.80% Profit Margin4.40% Rel Volume1.43 Prev Close59.46
ShortableYes LT Debt/Eq0.00 EarningsOct 26 AMC Payout0.00% Avg Volume100.27K Price60.85
Recom2.30 SMA205.63% SMA504.07% SMA2001.93% Volume143,263 Change2.34%
Jul-21-17Initiated Oppenheimer Outperform $74
Apr-28-17Reiterated Needham Buy $70 → $64
Feb-08-17Downgrade Pacific Crest Overweight → Sector Weight
Feb-08-17Downgrade Canaccord Genuity Buy → Hold $82 → $65
Dec-06-16Initiated The Benchmark Company Buy $84
Sep-30-16Initiated Pacific Crest Overweight $85
Sep-27-16Initiated First Analysis Sec Overweight $86
Sep-26-16Reiterated Needham Buy $70 → $83
Jul-27-16Reiterated Needham Buy $60 → $70
Jul-24-15Reiterated Stifel Buy $80 → $85
Jul-24-15Reiterated Northland Capital Outperform $82 → $87
Jul-24-15Reiterated Canaccord Genuity Buy $80 → $83
Jul-23-15Reiterated Needham Buy $72 → $86
Jun-28-13Reiterated Stifel Buy $46 → $60
Apr-26-13Reiterated Northland Capital Outperform $43 → $48
Apr-02-13Initiated Maxim Group Buy $50
Oct-26-12Reiterated Needham Buy $37 → $43
Oct-22-12Upgrade Canaccord Genuity Hold → Buy $45
Aug-08-12Reiterated Needham Buy $34 → $37
Jun-21-12Initiated Northland Securities Outperform $34
Oct-17-17 10:17AM  SPS Commerce, Inc. Value Analysis (NASDAQ:SPSC) : October 17, 2017 Capital Cube
Oct-16-17 08:21AM  SPS Commerce, Inc. breached its 50 day moving average in a Bullish Manner : SPSC-US : October 16, 2017 Capital Cube
Oct-12-17 04:05PM  SPS Commerce Announces Date of Third Quarter 2017 Financial Results GlobeNewswire
Oct-02-17 02:42PM  Should You Be Concerned About SPS Commerce Incs (SPSC) Risks? Simply Wall St.
Sep-15-17 08:02AM  See what the IHS Markit Score report has to say about SPS Commerce Inc. Markit
Sep-12-17 08:03AM  See what the IHS Markit Score report has to say about SPS Commerce Inc. Markit
Sep-07-17 09:04AM  Avis Budget's Zipcar Enters Latin America Through Costa Rica Zacks
Sep-06-17 08:01AM  See what the IHS Markit Score report has to say about SPS Commerce Inc. Markit
Sep-05-17 08:01AM  See what the IHS Markit Score report has to say about SPS Commerce Inc. Markit
Aug-29-17 09:07AM  SPS Commerce, Inc. breached its 50 day moving average in a Bullish Manner : SPSC-US : August 29, 2017 Capital Cube
Aug-23-17 10:00AM  SPS Commerce Releases Integrated Fulfillment for Acumatica GlobeNewswire
Aug-18-17 07:40AM  ABM Industries Augments UK Footprint With Key Contract Wins Zacks
Aug-14-17 08:02AM  See what the IHS Markit Score report has to say about SPS Commerce Inc. Markit
Aug-11-17 11:10PM  Edited Transcript of SPSC earnings conference call or presentation 27-Jul-17 8:30pm GMT Thomson Reuters StreetEvents
08:07AM  See what the IHS Markit Score report has to say about SPS Commerce Inc. Markit
Aug-01-17 04:05PM  SPS Commerce to Present at the Oppenheimer 20th Annual Technology, Internet & Communications Conference GlobeNewswire
11:58AM  SPS Commerce, Inc. :SPSC-US: Earnings Analysis: Q2, 2017 By the Numbers : August 1, 2017 Capital Cube
Jul-31-17 07:42PM  SPS Commerce, Inc. Value Analysis (NASDAQ:SPSC) : July 31, 2017 Capital Cube
Jul-27-17 04:05PM  SPS Commerce Reports Second Quarter 2017 Financial Results GlobeNewswire
11:30AM  Investor Network: SPS Commerce, Inc. to Host Earnings Call ACCESSWIRE
Jul-14-17 09:14AM  SPS Commerce, Inc. breached its 50 day moving average in a Bearish Manner : SPSC-US : July 14, 2017 Capital Cube
Jul-13-17 04:05PM  SPS Commerce Announces Date of Second Quarter 2017 Financial Results GlobeNewswire
Jul-11-17 03:03PM  ETFs with exposure to SPS Commerce, Inc. : July 11, 2017 Capital Cube
Jun-29-17 09:10AM  ABM to Save $13.7 Million in Energy Costs for Newton County Zacks
Jun-27-17 03:46PM  ETFs with exposure to SPS Commerce, Inc. : June 27, 2017 Capital Cube
08:45AM  Avis Budget Collaborates with Waymo for Self-Driving Cars Zacks
Jun-26-17 02:58PM  SPS Commerce, Inc. :SPSC-US: Earnings Analysis: Q1, 2017 By the Numbers : June 26, 2017 Capital Cube
May-30-17 09:00AM  SPS Commerce Announces Schedule of Upcoming Investor Conferences GlobeNewswire
May-16-17 09:11AM  Xerox Strengthens Foothold in Multi-Brand Retail Space Zacks
May-01-17 10:15AM  SPS Commerce Announces Comprehensive, Multi-Channel Demand Visibility for Retailing GlobeNewswire
10:15AM  SPS Commerce Ushers in New Era of Digital Product Data Management with Next Generation Assortment GlobeNewswire
09:00AM  SPS Commerce Unveils Enhanced Sourcing with Increased Visibility for Unified Retail Success GlobeNewswire
Apr-30-17 08:26AM  Edited Transcript of SPSC earnings conference call or presentation 27-Apr-17 8:30pm GMT Thomson Reuters StreetEvents
Apr-28-17 04:17PM  ETFs with exposure to SPS Commerce, Inc. : April 28, 2017 Capital Cube
Apr-27-17 06:20PM  SPS Commerce beats Street 1Q forecasts Associated Press
05:14PM  SPS Commerce, Inc. Value Analysis (NASDAQ:SPSC) : April 27, 2017 Capital Cube
04:05PM  SPS Commerce Reports First Quarter 2017 Financial Results GlobeNewswire
10:50AM  Investor Network: SPS Commerce, Inc. to Host Earnings Call Accesswire
Apr-26-17 09:20AM  SPS Commerce, Inc. breached its 50 day moving average in a Bearish Manner : SPSC-US : April 26, 2017 Capital Cube
Apr-13-17 04:05PM  SPS Commerce Announces Date of First Quarter 2017 Financial Results GlobeNewswire
Apr-12-17 09:00AM  Beyond Now: Retail Leaders to Share Insights on Todays Retail Transformation at SPS Commerce In:fluence 2017 GlobeNewswire
Apr-04-17 09:00AM  Retail Leaders Unite to Move Beyond Omnichannel at SPS Commerce In:fluence 2017 GlobeNewswire
09:00AM  Retail Leaders Unite to Move Beyond Omnichannel at SPS Commerce In:fluence 2017
Mar-03-17 01:04PM  SPS COMMERCE INC Financials
Feb-27-17 05:26PM  SPS COMMERCE INC Files SEC form 10-K, Annual Report
Feb-21-17 09:00AM  SPS Commerce to Present at the JMP Securities 2017 Technology Conference GlobeNewswire
Feb-15-17 04:26PM  SPS COMMERCE INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
Feb-09-17 12:17PM  SPS Commerce, Inc. :SPSC-US: Earnings Analysis: Q4, 2016 By the Numbers : February 9, 2017 Capital Cube
12:17PM  SPS Commerce, Inc. :SPSC-US: Earnings Analysis: Q4, 2016 By the Numbers : February 9, 2017
Feb-08-17 12:42PM  SPS Commerce, Inc. :SPSC-US: Earnings Analysis: 2016 By the Numbers : February 8, 2017 -18.86%
07:12AM  SPS Commerce downgraded by Pacific Crest and Canaccord Genuity
Feb-07-17 08:05PM  Edited Transcript of SPSC earnings conference call or presentation 7-Feb-17 9:30pm GMT Thomson Reuters StreetEvents
08:05PM  Edited Transcript of SPSC earnings conference call or presentation 7-Feb-17 9:30pm GMT
06:23PM  SPS Commerce beats Street 4Q forecasts Associated Press
04:08PM  SPS COMMERCE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  SPS Commerce Reports Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
07:07AM  Q4 2016 SPS Commerce Inc Earnings Release - After Market Close
Feb-01-17 03:03PM  SPS Commerce, Inc. Value Analysis (NASDAQ:SPSC) : February 1, 2017 Capital Cube
03:03PM  SPS Commerce, Inc. Value Analysis (NASDAQ:SPSC) : February 1, 2017
Jan-31-17 10:13AM  SPS Commerce, Inc. breached its 50 day moving average in a Bearish Manner : SPSC-US : January 31, 2017 Capital Cube
10:13AM  SPS Commerce, Inc. breached its 50 day moving average in a Bearish Manner : SPSC-US : January 31, 2017
Jan-26-17 02:20PM  More Retailers Get on Board With 'Drop Shipping' for E-Commerce The Wall Street Journal
02:20PM  More Retailers Get on Board With 'Drop Shipping' for E-Commerce at The Wall Street Journal
Jan-24-17 09:00AM  SPS Commerce In:fluence 2017 Empowers Attendees to Go Beyond with Inspirational Keynote Speakers GlobeNewswire
Jan-17-17 04:05PM  SPS Commerce Announces Date of Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
Jan-16-17 08:00AM  Retail Industry Moving Beyond Omnichannel as Consumers Demand Personalized Shopping Experiences Across Channels GlobeNewswire
Jan-10-17 09:10AM  SPS Commerce and Deposco Deliver Orchestrated Retail Solutions to Advance the Digital Supply Chain GlobeNewswire
Jan-03-17 04:05PM  SPS Commerce to Present at the 19th Annual Needham Growth Conference GlobeNewswire
Dec-21-16 06:57AM  Avis Closes France Cars Buyout to Boost Global Presence
Dec-19-16 08:35AM  Xerox's (XRX) Strategic Efforts Bode Well, Risks Remain
Dec-12-16 02:35AM  SPS Commerce, Inc. (SPSC): Are Hedge Funds Right About This Stock? at Insider Monkey
Dec-02-16 11:06AM  ETFs with exposure to SPS Commerce, Inc. : December 2, 2016
Dec-01-16 07:16AM  SPS Commerce, Inc. breached its 50 day moving average in a Bullish Manner : SPSC-US : December 1, 2016
Nov-10-16 09:30AM  Zacks.com featured highlights: SPS Commerce, CryoLife, FormFactor, Willdan Group and LegacyTexas Financial Group
Nov-09-16 08:01AM  Focus On 5 Best Profitable Stocks for Desirable Returns
Nov-04-16 09:30AM  Zacks.com featured highlights: Activision Blizzard, Gibraltar Industries, Northrop Grumman, SJW and SPS Commerce
Nov-03-16 10:15AM  Follow Driehaus' Rule & Pick These 5 Momentum Stocks
Oct-28-16 07:17PM  Edited Transcript of SPSC earnings conference call or presentation 27-Oct-16 8:30pm GMT -7.22%
04:05PM  SPS COMMERCE INC Files SEC form 10-Q, Quarterly Report
Oct-27-16 07:05PM  SPS Commerce tops Street 3Q forecasts AP
04:09PM  SPS COMMERCE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  SPS Commerce Reports Third Quarter 2016 Financial Results GlobeNewswire
07:07AM  Q3 2016 SPS Commerce Inc Earnings Release - After Market Close
Oct-26-16 09:14AM  Business Service Stocks Earnings on Oct 27: EXLS, FCN & More
Oct-25-16 05:05PM  Breakout Watch: RealPage Rallies Into Buy Zone Ahead Of Earnings
Oct-21-16 08:51AM  SPS Commerce, Inc. breached its 50 day moving average in a Bearish Manner : SPSC-US : October 21, 2016
Oct-06-16 04:05PM  SPS Commerce Announces Date of Third Quarter 2016 Financial Results GlobeNewswire
Sep-30-16 04:54PM  Four Top Software Stocks That Are Tough To Top
Sep-22-16 08:35AM  SPS Commerce (SPSC) in Focus: Stock Jumps 6.5% in Session
Sep-21-16 12:30AM  IHS Tears Down the iPhone 7, Mast Therapeutics Crashes On Trial Failure, Plus the Latest Hype On 3 Other Stocks at Insider Monkey +6.53%
Sep-20-16 06:14PM  The Cooper Companies Set to Join the S&P 500; Northwestern and NuVasive to Join S&P MidCap 400; SPS Commerce and Fox Factory to Join S&P SmallCap 600 PR Newswire
Sep-19-16 10:46AM  ETFs with exposure to SPS Commerce, Inc. : September 19, 2016
Sep-16-16 09:29AM  SPS Commerce, Inc. :SPSC-US: Earnings Analysis: Q2, 2016 By the Numbers : September 16, 2016
Aug-03-16 04:05PM  SPS Commerce Announces Schedule of Upcoming Investor Conferences GlobeNewswire
09:24AM  Avis (CAR) Q2 Earnings Miss, Stock Up on Raised 2016 View
Jul-29-16 04:23PM  SPS COMMERCE INC Files SEC form 10-Q, Quarterly Report
Jul-28-16 08:11AM  Edited Transcript of SPSC earnings conference call or presentation 27-Jul-16 8:30pm GMT
07:25AM  SPS Commerce tops Street 2Q forecasts AP
Jul-27-16 04:08PM  SPS COMMERCE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  SPS Commerce Reports Second Quarter 2016 Financial Results GlobeNewswire
SPS Commerce, Inc. provides cloud-based supply chain management solutions worldwide. It provides solutions through the SPS Commerce platform, a cloud-based product suite that enhances the way suppliers, retailers, distributors, logistics firms, and other trading partners manage and fulfill orders. The company offers Trading Partner Fulfillment solution, which provides fulfillment automation and replaces or augments an organization's existing trading partner electronic communication infrastructure; Trading Partner Analytics solution that comprises data analytics applications to enhance visibility and analysis of customers supply chains; and Trading Partner Assortment solution to manage individual attributes associated with each item a retailer or supplier sells. It also provides Trading Partner Sourcing solution that enables retailers to source providers of new items, suppliers to connect with new retailers, and retailing community to make connections for expanding their business networks and grow; Trading Partner Community Development solution, which offers communications programs that enables retailers, suppliers, and emerging providers of value-added products and services to establish trading partner relationships with new trading partners to expand their businesses; and Other Trading Partner Solutions, such as barcode labeling, planogram services, and scan and pack application that helps trading partners process information to streamline the picking and packaging process. The company sells its solutions primarily through retail sales professionals and supplier sales representatives to small- to mid-sized suppliers in the consumer packaged goods industry, as well as retailers, distributors, third-party logistics providers, and other trading partners. The company was formerly known as St. Paul Software, Inc. and changed its name to SPS Commerce, Inc. in May 2001. SPS Commerce, Inc. was incorporated in 1987 and is headquartered in Minneapolis, Minnesota.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Smerklo Michael ADirectorAug 29Sale61.3822713,933682Aug 31 05:32 PM
Smerklo Michael ADirectorJun 01Sale59.3776045,119909Jun 05 05:10 PM
Black Archie C.CEOMar 01Option Exercise16.6415,000249,600103,380Mar 03 06:05 PM
Black Archie C.CEOMar 01Sale55.8715,000837,99488,380Mar 03 06:05 PM
Frome James J.EVP & Chief Operating OfficerFeb 10Sale58.014,618267,88312,993Feb 14 08:10 PM
Frome James J.EVP & Chief Operating OfficerFeb 06Sale66.972,859191,46617,611Feb 08 05:18 PM
Black Archie C.CEOFeb 02Option Exercise16.645,37189,37373,971Feb 03 05:36 PM
Black Archie C.CEOFeb 02Sale68.135,371365,90368,600Feb 03 05:36 PM
Black Archie C.CEOFeb 01Option Exercise16.649,629160,22778,229Feb 03 05:36 PM
Black Archie C.CEOFeb 01Sale68.059,629655,23068,600Feb 03 05:36 PM
Black Archie C.CEOJan 04Option Exercise16.641,38523,04669,985Jan 05 05:26 PM
Black Archie C.CEOJan 04Sale70.031,38596,99568,600Jan 05 05:26 PM
Black Archie C.CEOJan 03Option Exercise16.6413,615226,55482,215Jan 05 05:26 PM
Black Archie C.CEOJan 03Sale69.2013,615942,11968,600Jan 05 05:26 PM
SORAN PHILIPDirectorNov 16Option Exercise27.552,67273,6147,938Nov 18 05:26 PM
SORAN PHILIPDirectorNov 16Sale66.282,672177,1025,266Nov 18 05:26 PM
Frome James J.EVP & Chief Operating OfficerNov 02Option Exercise25.323,94599,88724,415Nov 03 05:11 PM
Frome James J.EVP & Chief Operating OfficerNov 02Sale62.193,945245,34120,470Nov 03 05:11 PM
Frome James J.EVP & Chief Operating OfficerNov 01Option Exercise25.3212,023304,42232,493Nov 03 05:11 PM
Frome James J.EVP & Chief Operating OfficerNov 01Sale62.2512,023748,47020,470Nov 03 05:11 PM
CLDX Celldex Therapeutics, Inc. daily Stock Chart
CLDX [NASD]
Celldex Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.10 Insider Own0.40% Shs Outstand129.61M Perf Week-4.89%
Market Cap378.46M Forward P/E- EPS next Y-0.95 Insider Trans0.00% Shs Float127.49M Perf Month18.70%
Income-124.70M PEG- EPS next Q-0.27 Inst Own59.70% Short Float5.63% Perf Quarter22.18%
Sales9.50M P/S39.84 EPS this Y3.40% Inst Trans0.06% Short Ratio4.97 Perf Half Y-9.32%
Book/sh1.85 P/B1.58 EPS next Y8.70% ROA-37.20% Target Price7.30 Perf Year-15.12%
Cash/sh1.19 P/C2.46 EPS next 5Y- ROE-51.90% 52W Range2.20 - 5.02 Perf YTD-17.51%
Dividend- P/FCF- EPS past 5Y-2.20% ROI-50.10% 52W High-41.83% Beta2.67
Dividend %- Quick Ratio5.60 Sales past 5Y-6.00% Gross Margin- 52W Low32.73% ATR0.14
Employees205 Current Ratio5.60 Sales Q/Q171.40% Oper. Margin- RSI (14)52.67 Volatility4.42% 5.82%
OptionableYes Debt/Eq0.00 EPS Q/Q29.40% Profit Margin- Rel Volume0.50 Prev Close2.97
ShortableYes LT Debt/Eq0.00 EarningsNov 07 AMC Payout- Avg Volume1.44M Price2.92
Recom2.50 SMA20-2.46% SMA508.76% SMA200-1.69% Volume715,532 Change-1.68%
Aug-01-17Resumed H.C. Wainwright Buy $10
Nov-07-16Initiated Aegis Capital Buy
Mar-08-16Downgrade Jefferies Buy → Hold
Mar-07-16Downgrade Wedbush Outperform → Neutral $4
Mar-07-16Downgrade Leerink Partners Outperform → Mkt Perform
Mar-07-16Downgrade Guggenheim Buy → Neutral
Mar-01-16Initiated H.C. Wainwright Buy $25
Aug-11-15Reiterated ROTH Capital Buy $43 → $39
Aug-11-15Reiterated Oppenheimer Outperform $45 → $42
Aug-11-15Reiterated Brean Capital Buy $35 → $31
Jun-02-15Reiterated WBB Securities Strong Buy $30 → $40
Nov-17-14Reiterated ROTH Capital Buy $40 → $43
Mar-04-14Reiterated Oppenheimer Outperform $40 → $36
Jul-08-13Reiterated Cantor Fitzgerald Buy $16 → $24
Mar-08-13Reiterated Cantor Fitzgerald Buy $13 → $16
Feb-26-13Reiterated Oppenheimer Outperform $10 → $13
Jan-10-13Reiterated Cantor Fitzgerald Buy $9 → $13
Oct-02-12Reiterated Oppenheimer Outperform $6 → $8
Sep-14-12Reiterated Cantor Fitzgerald Buy $7 → $9
Apr-04-12Initiated Cantor Fitzgerald Buy $7
Oct-17-17 06:17PM  Better Buy: Ziopharm Oncology, Inc. vs. Celldex Therapeutics Motley Fool
Oct-06-17 03:13PM  What's Behind Celldex Therapeutics, Inc.'s 16% Rally in September? Motley Fool
Oct-03-17 08:00AM  Celldex Therapeutics Appoints Margo Heath-Chiozzi, M.D., as Senior Vice President, Regulatory Affairs GlobeNewswire
Oct-02-17 03:27PM  How Does Investing In Celldex Therapeutics Inc (CLDX) Impact Your Portfolio? Simply Wall St.
Sep-26-17 10:46AM  ETFs with exposure to Celldex Therapeutics, Inc. : September 26, 2017 Capital Cube -9.33%
08:10AM  Today's Research Reports on Trending Tickers: Celldex Therapeutics and Genocea Biosciences ACCESSWIRE
Sep-25-17 04:20PM  Why Celldex Therapeutics, Inc. Jumped Higher Today Motley Fool +12.78%
08:09AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : September 25, 2017 Capital Cube
Sep-22-17 08:00AM  Celldex Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire +8.13%
Sep-21-17 07:47AM  3 Small-Cap Biotech Stocks to Buy This Fall Motley Fool
Sep-12-17 04:01PM  Celldex Announces Departure of Chief Medical Officer GlobeNewswire
Sep-11-17 10:18PM  ETFs with exposure to Celldex Therapeutics, Inc. : September 12, 2017 Capital Cube
Sep-08-17 08:00AM  Today's Research Reports on Trending Tickers: AVEO Pharmaceuticals, Inc. and Celldex Therapeutics, Inc. ACCESSWIRE -5.80%
Aug-31-17 05:44PM  ETFs with exposure to Celldex Therapeutics, Inc. : August 31, 2017 Capital Cube
Aug-29-17 08:35AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : August 29, 2017 Capital Cube
Aug-24-17 10:03PM  3 Top Healthcare Stocks to Buy Now Motley Fool
05:42PM  Celldex Ends Phase II Enrollment for Breast Cancer Candidate Zacks
11:33AM  Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-23-17 09:15AM  Celldex Announces Completion of Enrollment in Phase 2b Study of Glembatumumab Vedotin in Triple Negative Breast Cancer GlobeNewswire
Aug-19-17 12:03PM  3 Top Biotech Stocks Under $10 Motley Fool
Aug-16-17 08:15PM  Celldex Therapeutics, Inc. Value Analysis (NASDAQ:CLDX) : August 17, 2017 Capital Cube
Aug-14-17 09:37AM  3 Beaten-Up Biotech Stocks: Are They Bargains? Motley Fool
08:26AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : August 14, 2017 Capital Cube
02:11AM  Edited Transcript of CLDX earnings conference call or presentation 8-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-09-17 10:48AM  Celldex (CLDX) Q2 Loss Narrows, Revenues Beat, Shares Up Zacks
08:02AM  Celldex Therapeutics, Inc. Finishes Second Quarter With Plenty of Cash and Clinical Momentum Motley Fool
Aug-08-17 11:55PM  Celldex reports 2Q loss Associated Press
04:01PM  Celldex Reports Second Quarter 2017 Results GlobeNewswire
Aug-04-17 08:22AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : August 4, 2017 Capital Cube
Aug-02-17 11:30AM  Celldex to Report Second Quarter 2017 Financial Results and Host Corporate Update Call GlobeNewswire
09:20AM  What's in the Cards for Celldex (CLDX) this Earnings Season? Zacks
Jul-19-17 06:30AM  Better Buy: Celldex Therapeutics, Inc. vs. Juno Therapeutics Motley Fool
Jul-14-17 07:01PM  Down 14.8%: Is Celldex Therapeutics Stock an Incredible Bargain? Motley Fool
Jun-24-17 11:42AM  3 Stocks That Could Double Your Money Motley Fool
Jun-18-17 02:32PM  3 Stocks with Universal Display-like Return Potential Motley Fool
Jun-16-17 08:01AM  Celldex Therapeutics Announces Additions to the Board of Directors and Senior Management Team GlobeNewswire
Jun-13-17 07:17AM  Why Is Celldex (CLDX) Down 27% Since the Last Earnings Report? Zacks
Jun-12-17 08:42AM  3 Beaten-Up Biotech Stocks: Are They Bargains? Motley Fool
Jun-11-17 09:47AM  3 Stocks That Look Just Like Oracle in 1986 Motley Fool
Jun-07-17 08:00AM  Today's Research Reports on Stocks to Watch: Celldex Therapeutics and Pandora Media Accesswire -5.86%
Jun-06-17 04:53PM  Here's Why Celldex Therapeutics, Inc. Fell Today Motley Fool -12.45%
04:01PM  Celldex Therapeutics to Participate in the Jefferies 2017 Global Healthcare Conference GlobeNewswire
Jun-05-17 04:27PM  Celldex Therapeutics Presents Phase 1 Study of Varlilumab and Opdivo® at 2017 ASCO Annual Meeting GlobeNewswire -5.54%
04:17PM  Here's What Shaved 14% Off Celldex Therapeutics, Inc.'s Stock Price in May Motley Fool
02:08PM  ETFs with exposure to Celldex Therapeutics, Inc. : June 5, 2017 Capital Cube
11:24AM  Celldex Presents Promising Overall Survival Data from Phase 2 Study of Single-agent Glembatumumab Vedotin in Patients with Checkpoint-Refractory Metastatic Melanoma GlobeNewswire
Jun-02-17 09:49AM  Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
Jun-01-17 09:39AM  Celldex Therapeutics, Inc.: The Bear Case from a Bull Motley Fool
May-30-17 12:26PM  George O. Elston Named Chief Executive Officer of 2X Oncology GlobeNewswire
May-26-17 09:31AM  Celldex's Immuno-Oncology Pipeline Continues to Impress Zacks
May-21-17 06:41AM  Better Buy: Celldex Therapeutics, Inc. vs. Agenus Inc. Motley Fool
May-18-17 07:44AM  3 Value Stocks for Bold Investors Motley Fool
May-17-17 05:01PM  Celldex Therapeutics to Present Clinical Results at 2017 ASCO Annual Meeting GlobeNewswire
May-10-17 10:30AM  Celldex (CLDX) Q1 Loss In Line, Revenues Beat, Shares Up Zacks
08:50AM  3 Stocks That Could Double Your Investment Motley Fool
May-09-17 05:41PM  Celldex Therapeutics, Inc.'s Collaboration with Bristol-Myers Squibb Key in First-Quarter Update Motley Fool
05:34PM  Celldex reports 1Q loss Associated Press
04:01PM  Celldex Reports First Quarter 2017 Results GlobeNewswire
May-02-17 11:33AM  Celldex Therapeutics (CLDX) Q1 Earnings: What's in Store? Zacks
Apr-23-17 02:03PM  Read This Before You Buy Biotech Stocks Motley Fool
Apr-21-17 07:30AM  Today's Research Reports on Biotech Stocks to Watch: Celldex Therapeutics and Spectrum Pharmaceuticals Accesswire
Apr-20-17 10:21AM  Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards? Zacks
10:16AM  What's in Store for Biogen (BIIB) this Earnings Season? Zacks
Apr-19-17 02:16PM  ETFs with exposure to Celldex Therapeutics, Inc. : April 19, 2017 Capital Cube
03:26AM  Why Is Celldex (CLDX) Down 4.4% Since the Last Earnings Report? Zacks
Apr-17-17 08:42AM  3 Cancer Drug Stocks That Could Make You Rich Motley Fool
Apr-15-17 12:02PM  3 Biotech Stocks to Buy on Sale Motley Fool
Apr-07-17 04:11PM  ETFs with exposure to Celldex Therapeutics, Inc. : April 7, 2017 Capital Cube
11:09AM  3 Stocks That Could Double Your Money Motley Fool
Apr-01-17 12:02PM  3 Top Stocks You've Been Overlooking Motley Fool
12:02PM  3 Top Stocks You've Been Overlooking at Motley Fool
Mar-31-17 09:30AM  Today's Research Reports on Stocks to Watch: Celldex Therapeutics and PDL BioPharma Accesswire
Mar-30-17 08:12AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : March 30, 2017 Capital Cube
08:12AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : March 30, 2017
Mar-27-17 03:52PM  ETFs with exposure to Celldex Therapeutics, Inc. : March 27, 2017 Capital Cube
03:52PM  ETFs with exposure to Celldex Therapeutics, Inc. : March 27, 2017
Mar-25-17 12:03PM  3 Stocks That Could Double Your Money at Motley Fool
Mar-21-17 09:25AM  Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Capital Cube -5.93%
09:25AM  Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
Mar-20-17 10:01AM  Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: 2016 By the Numbers : March 20, 2017
Mar-18-17 01:04PM  CELLDEX THERAPEUTICS, INC. Financials
Mar-17-17 08:10AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : March 17, 2017
Mar-15-17 10:55AM  Celldex (CLDX) Shares Up as Q4 Loss Narrows; Sales Beat Zacks
12:58AM  Edited Transcript of CLDX earnings conference call or presentation 14-Mar-17 8:30pm GMT Thomson Reuters StreetEvents
Mar-14-17 06:23PM  Celldex Therapeutics, Inc. Ends Q4 With Plenty of Cash and Several Key Studies Progressing Motley Fool
06:23PM  Celldex Therapeutics, Inc. Ends Q4 With Plenty of Cash and Several Key Studies Progressing at Motley Fool
04:30PM  Celldex Therapeutics Inc Earnings and Corporate Strategy Call scheduled for 4:30 pm ET today
04:26PM  CELLDEX THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
04:14PM  Celldex reports 4Q loss Associated Press
04:01PM  Celldex Provides Corporate Update and Reports Full Year 2016 Results GlobeNewswire
07:07AM  Q4 2016 Celldex Therapeutics Inc Earnings Release - After Market Close
Mar-12-17 07:21AM  3 Horrible Stocks for Retirees at Motley Fool
Mar-10-17 02:42PM  Better Buy: Agenus Inc. vs. Celldex Therapeutics at Motley Fool
Mar-09-17 09:15AM  Spectrum (SPPI) Q4 Loss Narrower than Expected, Sales Beat
Mar-08-17 09:30AM  Biotech and Pharmaceutical Stocks Fall on Pricing Concerns: Today's Research Reports on Celldex Therapeutics and Mast Therapeutics Accesswire
Mar-07-17 04:43PM  Celldex Therapeutics, Inc. Is Feeling Some Pressure Today -- Here's Why at Motley Fool -9.19%
Mar-06-17 11:03AM  Why Celldex Therapeutics Stock Gained 10% in February at Motley Fool
08:46AM  Celldex Therapeutics (CLDX) Q4 Earnings: What's in Store?
Mar-03-17 08:03AM  3 Stocks That Could Double Your Money at Motley Fool
Mar-01-17 04:05PM  CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, F
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers. In addition, the company focuses on the discovery and development of antibody-based drugs targeting receptor tyrosine kinases, such as CDX-0158, a humanized monoclonal antibody currently in a Phase 1 dose escalation study in refractory gastrointestinal stromal tumors and other KIT positive tumors; and CDX-3379, a human monoclonal antibody, which has completed a Phase 1b study in patients with solid tumors. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. The company is headquartered in Hampton, New Jersey.
DAC Danaos Corporation daily Stock Chart
DAC [NYSE]
Danaos Corporation
Index- P/E- EPS (ttm)-3.79 Insider Own58.70% Shs Outstand102.47M Perf Week-3.33%
Market Cap148.58M Forward P/E1.56 EPS next Y0.93 Insider Trans0.00% Shs Float19.58M Perf Month7.41%
Income-416.30M PEG- EPS next Q0.23 Inst Own2.00% Short Float2.33% Perf Quarter-30.95%
Sales447.80M P/S0.33 EPS this Y-412.90% Inst Trans-0.23% Short Ratio5.25 Perf Half Y-12.12%
Book/sh4.50 P/B0.32 EPS next Y4.49% ROA-12.90% Target Price3.00 Perf Year-44.66%
Cash/sh0.62 P/C2.33 EPS next 5Y3.00% ROE-69.90% 52W Range1.25 - 4.40 Perf YTD-45.28%
Dividend- P/FCF0.68 EPS past 5Y26.80% ROI-7.10% 52W High-67.05% Beta1.32
Dividend %- Quick Ratio0.00 Sales past 5Y1.30% Gross Margin72.90% 52W Low16.00% ATR0.10
Employees1196 Current Ratio0.10 Sales Q/Q-16.90% Oper. Margin-57.40% RSI (14)49.50 Volatility6.63% 6.44%
OptionableNo Debt/Eq4.87 EPS Q/Q-54.70% Profit Margin-93.00% Rel Volume0.41 Prev Close1.45
ShortableYes LT Debt/Eq0.00 EarningsOct 30 AMC Payout- Avg Volume87.01K Price1.45
Recom3.00 SMA20-0.17% SMA50-1.86% SMA200-20.36% Volume35,474 Change0.00%
Feb-20-15Initiated Global Hunter Securities Neutral
Sep-18-14Resumed Clarkson Capital Hold
Apr-17-13Initiated Global Hunter Securities Neutral
Apr-24-09Downgrade Jefferies & Co Buy → Hold $6 → $5
Mar-13-09Reiterated Jefferies & Co Buy $22 → $6
Nov-04-08Reiterated Jefferies & Co Buy $46 → $22
Jan-29-08Initiated Oppenheimer Outperform $36
Nov-20-07Initiated Lazard Capital Buy $39
Jul-18-07Initiated Credit Suisse Outperform $37
Jan-25-07Reiterated Fortis Bank Buy $23 → $27
Sep-11-17 01:26PM  Danaos Corp. :DAC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017 Capital Cube +7.14%
Aug-01-17 07:20AM  Investor Network: Danaos Corporation to Host Earnings Call ACCESSWIRE
Jul-31-17 10:06PM  Danaos posts 2Q profit Associated Press
04:30PM  Danaos Corporation Reports Second Quarter and Half Year Results for the Period Ended June 30, 2017 PR Newswire
Jul-28-17 04:30PM  Danaos Corporation Announces Date for the Release of Second Quarter 2017 Results, Conference Call and Webcast PR Newswire
Jul-13-17 11:46AM  Top Ranked Value Stocks to Buy for July 13th Zacks +18.92%
Jul-12-17 09:45AM  New Strong Buy Stocks for July 12th Zacks +17.46%
Jun-30-17 06:07AM  Will Danaos (DAC) Continue to Surge Higher? Zacks
Jun-28-17 10:44AM  Top Ranked Value Stocks to Buy for June 28th Zacks
08:15AM  Earnings Review and Free Research Report: Dynagas Reports Better Than Expected Earnings Accesswire
Jun-26-17 02:59PM  Danaos Corp. :DAC-US: Earnings Analysis: Q1, 2017 By the Numbers : June 26, 2017 Capital Cube +6.06%
Jun-22-17 10:00AM  Top Ranked Value Stocks to Buy for June 22nd Zacks
May-30-17 04:38PM  Danaos posts 1Q profit Associated Press +8.00%
04:30PM  Danaos Corporation Reports First Quarter Results for the Period Ended March 31, 2017 PR Newswire
May-24-17 04:30PM  Danaos Corporation Announces Date for the Release of First Quarter 2017 Results, Conference Call and Webcast PR Newswire +8.00%
Mar-17-17 08:20AM  Danaos (DAC) Shows Strength: Stock Moves 15.2% Higher Zacks +5.26%
Mar-16-17 08:23AM  Danaos Corp. :DAC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 16, 2017 Capital Cube +15.15%
08:23AM  Danaos Corp. :DAC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 16, 2017
Mar-15-17 01:01PM  Danaos Corp. :DAC-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017
Mar-10-17 01:04PM  DANAOS CORP Financials -5.26%
Mar-06-17 04:58PM  Danaos Corporation Announces Availability of its Annual Report on Form 20-F for the Year Ended December 31, 2016 PR Newswire
Feb-21-17 06:04PM  Danaos reports 4Q loss Associated Press
04:30PM  Danaos Corporation Reports Results for the Fourth Quarter and Year Ended December 31, 2016 PR Newswire
07:07AM  Q4 2016 Danaos Corp Earnings Release - After Market Close
Feb-15-17 04:30PM  Danaos Corporation Announces Date for the Release of Fourth Quarter 2016 Results, Conference Call and Webcast PR Newswire
Dec-22-16 11:07AM  What Makes Danaos (DAC) a Strong Sell? Zacks
Dec-16-16 11:30AM  DryShips Shares Float Higher Again With New Loan TheStreet.com
11:30AM  DryShips Shares Float Higher Again With New Loan
Dec-15-16 04:40PM  Danaos reports 3Q loss +5.17%
04:30PM  Danaos Corporation Reports Third Quarter and Nine Months Results for the Period Ended September 30, 2016 PR Newswire
07:07AM  Q3 2016 Danaos Corp Earnings Release - After Market Close
Dec-13-16 04:48PM  Danaos Corporation Announces Date for the Release of Third Quarter 2016 Results, Conference Call and Webcast PR Newswire
Nov-21-16 08:26AM  Shipping Stocks' Q3 Earnings Round the Corner: GOGL, DAC
Nov-16-16 06:08PM  Why Fossil Group, Advanced Micro Devices, and Danaos Jumped Today at Motley Fool +8.96%
03:24PM  Danaos Corp.: Price momentum supported by strong fundamentals
07:39AM  Danaos Corp. breached its 50 day moving average in a Bullish Manner : DAC-US : November 16, 2016
Nov-15-16 04:02PM  Why Shipping Stocks Skyrocketed Higher Today at Motley Fool +42.55%
Nov-08-16 09:39AM  Best of the Worst: Can We Find a Container Shipping Company to Invest In? at Motley Fool -8.00%
Nov-07-16 07:27AM  Transport Stock Earnings to Watch on Nov 8 - EXPD, TGH, DAC
Oct-10-16 09:00AM  Capital Link's 6th Annual Operational Excellence & Maritime CSR Forum Wednesday, November 2, 2016 in London, UK Marketwired
Sep-09-16 04:26PM  Danaos Corp.: Price momentum supported by strong fundamentals
Sep-01-16 08:00AM  Danaos Corporation Receives Notice that Counterparty has Entered into Court Receivership PR Newswire -11.46%
Aug-30-16 01:45PM  Will Seaspan Corporation Raise Its Dividend in 2017? at Motley Fool
Aug-18-16 08:09AM  Danaos Corp. breached its 50 day moving average in a Bearish Manner : DAC-US : August 18, 2016
Aug-15-16 04:15PM  3 Things Seaspan Corporation's CEO Wants You to Know at Motley Fool
Aug-11-16 05:24AM  Navigator Holdings (NVGS) in Focus: Stock Up 7% in Session
Aug-10-16 01:11PM  Danaos Corp. :DAC-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016
08:34AM  Should You Get Rid of Kirby (KEX) Now?
Aug-03-16 09:30AM  Zacks.com featured highlights: Danaos, Telecom Italia, Fibria Celulose, Goodyear Tire & Rubber and Zafgen
08:25AM  Ardmore Shipping (ASC) in Focus: Stock Moves 9.4% Higher
Aug-01-16 05:06PM  Danaos posts 2Q profit
04:30PM  Danaos Corporation Reports Second Quarter and Half Year Results for the Period Ended June 30, 2016 PR Newswire
07:07AM  Q2 2016 Danaos Corp Earnings Release - After Market Close
Jul-29-16 08:39AM  Transport Stocks' Q2 Earnings on Aug 1: DAC, RAIL & Others
Jul-25-16 08:51AM  What Makes Navigator Holdings (NVGS) a Strong Sell?
Jul-21-16 04:30PM  Danaos Corporation Announces Date for the Release of Second Quarter 2016 Results, Conference Call and Webcast Marketwired
Jul-20-16 08:05AM  Star Bulk Carriers (SBLK) in Focus: Stock Up 5.3% in Session +5.57%
Jul-19-16 09:30AM  Zacks.com featured highlights: Stamps.com, ReneSola and Danaos
08:30AM  Capital Product (CPLP) Soars: Stock Adds 7.6% in Session
Jul-18-16 03:39PM  Danaos Corp. Value Analysis (NYSE:DAC) : July 18, 2016 +7.43%
Jul-12-16 06:53AM  Can the Rally in Danaos (DAC) Shares Continue?
Jul-11-16 08:54AM  Danaos Corp. breached its 50 day moving average in a Bullish Manner : DAC-US : July 11, 2016 +5.94%
Jul-08-16 08:35AM  Aegean Marine Petroleum (ANW) in Focus: Stock Jumps 5.6% +23.17%
08:05AM  3 Reasons Why Danaos Corporation (DAC) is a Great Value Stock
Jul-07-16 08:58AM  Why Scorpio Tankers (STNG) Could Be Positioned for a Slump +11.19%
08:25AM  Danaos (DAC) Shows Strength: Stock Adds 8.5% in Session
Jun-21-16 10:29AM  Maersk battles to stay on top as container shipping downturn deepens
Jun-17-16 03:15PM  Seaspan Corporation Refuses to Throw a Lifeline to a Sinking Customer at Motley Fool
May-31-16 10:05AM  Has Seaspan Corporation Done Enough to Shore Up Its Finances? at Motley Fool
May-23-16 04:14PM  Danaos Corp.: Price momentum supported by strong fundamentals -5.48%
May-10-16 09:05AM  Industry Leaders at Capital Link's Analyst & Investor Day on June 6, 2016 at Athens, Greece Marketwired
May-06-16 11:29AM  Danaos Corp. :DAC-US: Earnings Analysis: Q1, 2016 By the Numbers -12.95%
May-04-16 06:42PM  Danaos posts 1Q profit +6.10%
04:30PM  Danaos Corporation Reports First Quarter Results for the Period Ended March 31, 2016 Marketwired
07:07AM  Q1 2016 Danaos Corp Earnings Release - After Market Close
Apr-21-16 04:39PM  Danaos Corporation Announces Date for the Release of First Quarter 2016 Results, Conference Call and Webcast Marketwired
Mar-29-16 04:14PM  Greek Billionaire George Economou Buys More Shares of Danaos Corp (DAC) at Insider Monkey
Mar-18-16 08:30AM  Danaos Corporation Announces Availability of Its Annual Report on Form 20-F for the Year Ended December 31, 2015 Marketwired
Feb-18-16 10:28AM  Danaos Corp. Earnings Analysis: 2015 By the Numbers
Feb-16-16 05:23PM  Danaos beats 4Q profit forecasts
04:46PM  Danaos Corporation Reports Results for the Fourth Quarter and Year Ended December 31, 2015 Marketwired
07:07AM  Q4 2015 Danaos Corp Earnings Release - After Market Close
Feb-10-16 09:30AM  New Strong Buy Stocks for February 10th
Feb-02-16 05:24PM  Danaos Corp. Value Analysis (NYSE:DAC) : February 2, 2016
08:05AM  Navigator Holdings (NVGS) in Focus: Stock Rises 6.5%
08:02AM  Danaos Corp. breached its 50 day moving average in a Bullish Manner : February 2, 2016
Feb-01-16 09:10AM  Danaos Corporation Announces Date for the Release of Fourth Quarter 2015 Results, Conference Call and Webcast at noodls
09:00AM  Danaos Corporation Announces Date for the Release of Fourth Quarter 2015 Results, Conference Call and Webcast Marketwired
Jan-22-16 08:30AM  KNOT Offshore Partners (KNOP) Jumps: Stock Rises 6.7%
Jan-21-16 08:40AM  Capital Product Partners (CPLP) Jumps: Stock Rises 5.6%
Jan-15-16 02:43PM  Edited Transcript of DAC earnings conference call or presentation 4-Nov-15 2:00pm GMT -5.49%
Jan-13-16 09:30AM  The Zacks Analyst Blog Highlights: Aegean Marine Petroleum Network, Danaos, Tsakos Energy Navigation, Horizon Pharma and ICON Public Limited
Jan-12-16 02:18PM  5 Smart PIIGS Stocks to Buy Now
Jan-01-16 08:01AM  Danaos Corp. breached its 50 day moving average in a Bullish Manner : January 1, 2016
Dec-31-15 04:13PM  Danaos Corp.: Strong price momentum but will it sustain? +8.12%
08:25AM  Danaos Corporation (DAC) Looks Good: Stock Adds 14.9%
Dec-30-15 08:30AM  Diana Containerships (DCIX) Looks Good: Stock Up 5.3% +14.94%
Dec-18-15 09:48AM  Danaos Corp. Earnings Analysis: Q3, 2015 By the Numbers
08:30AM  Teekay Corporation (TK) in Focus: Stock Plunges 58.4%
Dec-14-15 08:55AM  Danaos Corp Stock: 3 Reasons Why DAC Is a Top Choice for Value Investors
Danaos Corporation, together with its subsidiaries, owns and operates containerships in Australia, Asia, and Europe. The company offers seaborne transportation services, such as chartering its vessels to liner companies. As of February 28, 2017, it had a fleet of 55 containerships aggregating 329,588 twenty foot equivalent units. The company was formerly known as Danaos Holdings Limited and changed its name to Danaos Corporation in October 2005. Danaos Corporation was founded in 1972 and is based in Piraeus, Greece.